Test tube in lab

Pipeline

The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.
Candidate Selection
Preclinical PoC
Glp toxicology
Phase I/IIa
iTANK therapies
POC: Proof-of-Concept
GLP: Good Laboratory Practice
BCL: B-Cell Lymphoma
GBM: Glioblastoma Multiforme (brain tumor)
NET: Neuroendocrine tumors

CAR T in non-solid tumors – ELC-301

CAR T-cell therapy for treatment of Non-Hodgkin's B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of cancer that originates in the B cells of the immune system. DLBCL is one of the world's most common B-cell cancers and the disease has a rapid progression, which requires treatment to be initiated as soon as possible after the diagnosis is established. ELC-301 is being developed for patients suffering from a particularly severe form of DLBCL or who suffer relapse after several rounds of standard treatment.

Today's standard treatment consists of a combination of chemotherapy and antibodies and 60-70% of patients are cured. In patients who suffer relapse, CAR T-cell therapy is the next step in the treatment ladder. Despite the fact that the disease disappears in many after CAR T-cell treatment, the relapse rate is high in the patient group – up to 50% – and treatment options in the form of more advanced therapies are limited.

Today's approved CAR T-cell therapies target the tumor target CD19 – a common B-cell protein that is overproduced on the surface of cancer cells in DLBCL. In many of the individuals who suffer from relapse, this tumor target disappears and further treatments with the same CAR T therapy therefore become ineffective. ELC-301 instead targets CD20, which is also overrepresented in B-cell lymphoma. By switching targets to CD20, ELC-301 enables the treatment of relapsed patients who are in need of a new effective alternative.

In preclinical studies, ELC-301 has been shown to be able to induce an immune response that kills even those cancer cells that do not express the CAR T-cell antigen.

The Company has an ongoing Phase I/IIa clinical trial, called CARMA, with ELC-301 in a total of 18 cancer patients. The trial is conducted in two parts: a dose-escalation study, which has been completed, and a dose-optimization study. The first part was carried out in three cohorts of three, three and six patients, and aimed to identify the maximum tolerated dose (MTD) of ELC-301. In the second, ongoing part, a total of six patients are being treated in order to define the treatment dose for continued clinical development.

‍
CARMA has been supported by a grant from the European Innovation Council's Accelerator Fund.

  • The European Innovation Council is Europe’s flagship innovation programme to identify, develop and scale up breakthrough technologies and game changing innovations The EIC has been established under the EU Horizon Europe programme. It has a budget of €10.1 billion to support game changing innovations throughout the lifecycle from early stage research, to proof of concept, technology transfer, and the financing and scale up of start-ups and SMEs.
  • Only the most innovative companies get selected. The competition is intense and only the best quality proposals get funded.

‍

‍

CAR T in solid tumors – ELC-401

A new CAR T-cell therapy for the initial treatment of brain tumors with immune enhancement via the iTANK-platform

Glioblastoma (glioblastoma; GBM) is an aggressive form of brain cancer with a very high mortality rate, the expected survival of people diagnosed is about 15 months. In the US alone, approximately 15,000 individuals are affected by GBM and this form of cancer is expected to become more common, mainly due to the lack of effective cures. An aggravating factor in the development of drugs in the central nervous system is to enable the drug to cross the blood-brain barrier. Due to many setbacks in the pharmaceutical industry's attempts to overcome this challenge, GBM is currently treated primarily through surgery and radiation therapy.

ELC-401 targets the tumor antigen IL13Ra2 – a receptor protein that is overrepresented in GBM. In a preclinical study, the company has been able to show that IL13Ra2 is an effective tumor target for iTANK-enhanced CAR T-cells. The study, published in Nature Communications in 2023, evaluated the synthetic receptor underlying ELC-401. The results showed, among other things, that the CAR T-cells had a potent cell-killing effect and prolonged survival in the disease model.

Thanks to iTANK, ELC-401 is also expected to be able to counteract the highly immunosuppressive microenvironment in glioblastoma and mobilize an immune response against other targets in this heterogeneous form of cancer.

ELC-401 is currently in the clinical planning phase, and the Company is conducting process development and technology transfer of the manufacturing process to the selected manufacturing partner.

Next generation oncolytic virus – ELC-201

Next-generation oncolytic immunotherapy with three combined mechanisms of action.

Elicera's next-generation oncolytic immunotherapy, ELC-201, is based on a genetically modified adenovirus vector, armed with the company's proprietary iTANK-technology and a trans gene for 4-1BBL. The treatment is expected to work synergistically with established immune checkpoint inhibitors and can theoretically be used for the treatment of all injectable solid tumors.

Oncolytic virus in NET – ELC-100

AdVince – Oncolytic virus in a completed Phase I/IIa study, sponsored by Uppsala University, for the treatment of neuroendocrine tumors

Elicera's oncolytic virus AdVince (ELC-100) is based on a genetically modified adenovirus, Ad5PTD, that has been optimized with regards to its ability to selectively infiltrate and replicate in neuroendocrine cancer cells. When new virus particles have formed in enough numbers, tumor cells burst through a so-called immunogenic oncolysis, releasing factors that can also activate the immune system. When the tumor cell dies, an immune response to the cancer is also triggered by the release of neoantigens which are picked up by the patient's antigen-presenting dendritic cells, which then train T-cells in to attack cancer cells wherever they are in the body. In this way, AdVince is expected to achieve a local tumor-killing effect in the injected tumor while simultaneously triggering a long-term and systemic immune response through a T-cell attack on cancer cells in other parts of the body as well.

Clinical trials

ELC-301 is currently undergoing a Phase I/IIa clinical trial called CARMA. The study evaluates the safety, optimal dosing and preliminary efficacy of ELC-301 in patients with relapsed or refractory B-cell lymphoma who have received at least two prior lines of standard therapy and have no remaining curative treatment options. The study includes a dose-escalation phase (Phase I) with twelve patients in three cohorts to identify the maximum tolerated dose, followed by further evaluation of six patients in an expansion phase (Phase IIa).

The Phase I part of the study has been completed and showed that eight of twelve patients achieved a complete metabolic response (CMR, disease-free) as their best response during follow-up, and eleven patients had an objective tumor response. Six patients remained in CMR at their most recent assessment. The disease control rate was 100% and the objective response rate was 92% (11/12).

https://clinicaltrials.gov/search?term=elicera&viewType=Card

‍

ELC-100 has completed a Phase I/IIa clinical trial, sponsored by Uppsala University (ClinicalTrials.gov Identifier: NCT02749331)*, where the primary objective was to evaluate the safety of the treatment and determine the maximum tolerated dose for continued clinical development.

inal data from the Phase I/IIa clinical trial showed that ELC-100 was generally well tolerated, with no dose-limiting toxicity observed. Notably, the study also showed promising signs of efficacy, including partial tumor responses in two of eight patients evaluable for efficacy, providing early evidence of antitumor activity in this highly treatment-resistant patient population.

* https://clinicaltrials.gov/ct2/show/NCT02749331?term=advince&draw=2&rank=1

Patent portfolio

Drug Candidate
Title
Year of application
Patent approved
Expiration date
ELC-100/AdVince
Hexon TAT-PTD Modified Adenovirus and uses thereof
2013
USA
2033
ELC-201
Adenovirus for treatment of cancer
2021
Japan
2041
ELC-301 and ELC-001 (the iTANK-platform)
T-Cell Immunotherapy
2016
Turkey, United Kingdom,Switzerland, Europe (exceptCyprus, Greece, Ireland, Croatia,Romania, Slovakia, Czech Republicand Hungary) and China.
2036
ELC-401
CAR T IL-13Ra2
2020
Japan, USA, China
2041
  • iTANK platform: The patent application is in national-phase and protects a virus vector encoding a CAR and NAP.
  • ELC-100 (AdVince): Approved product patent in the United States.
  • ELC-201 (next generation oncolytic virus with three combined mode-of-actions): patent application submitted in 2021 and is approved in Japan.
  • ELC-301 (next-generation CAR T cells, initially for NHL treatment): The product is protected by the patent application filed for the iTANK platform and ELC-301 is not considered to be dependent on any other third party patents.
  • ELC-401 (next generation CAR T-cells, initially for the treatment of glioblastoma): A patent to protect the product was filed in April 2020 and is approved in Japan & USA. ELC-401 also includes the iTANK platform to provide a broad and strong immune response against cancer.